Detalles de la búsqueda
1.
Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selection.
Pharm Stat
; 22(6): 1076-1088, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37550963
2.
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.
J Antimicrob Chemother
; 72(1): 235-239, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27655859
3.
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV Clin Trials
; 13(4): 228-32, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22849964
4.
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clin Infect Dis
; 53(8): 807-16, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21921224
5.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20074791
6.
Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database.
Headache
; 51(3): 356-368, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21039453
7.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet
; 374(9692): 796-806, 2009 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19647866
8.
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Lancet HIV
; 5(12): e715-e722, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527329
9.
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
Open Forum Infect Dis
; 4(1): ofw047, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28480227
10.
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
Antivir Ther
; 20(3): 307-15, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25350973
11.
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
J Acquir Immune Defic Syndr
; 63(1): 77-85, 2013 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23412015
12.
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Lancet Infect Dis
; 11(12): 907-15, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21933752
13.
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
J Acquir Immune Defic Syndr
; 55(1): 39-48, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20404738
14.
The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain.
Curr Med Res Opin
; 23(1): 195-206, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17207303
Resultados
1 -
14
de 14
1
Próxima >
>>